170 Folgen

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Internal Medicine Audio PeerVoice

    • Wissenschaft

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

    Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

    Visit https://www.peervoice.com/GYE860 to view the entire programme with slides. After completing “Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics”, participants will be able to: Assess available safety and efficacy data from randomised clinical trials evaluating first- and next-generation FLT3 inhibitors in acute myeloid leukaemia (AML); Implement best practice approaches to using FLT3 inhibitors in practice, including selecting between therapeutics and utilising recommended dose schedules; and Formulate adverse event management strategies for patients with newly diagnosed FLT3-mutant AML receiving a FLT3 inhibitor, including monitoring and supportive treatment.

    • 22 Min.
    Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

    Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

    Visit https://www.peervoice.com/UGT860 to view the entire programme with slides. After completing “Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer ”, participants will be able to: Assess the clinical relevance of randomised controlled trial (RCT) data evaluating the safety and efficacy of TROP2-directed therapies in the management of HR+/HER2- advanced breast cancer; and Identify patients with HR+/HER2- advanced breast cancer who may benefit from treatment with a TROP2-directed therapy.

    • 21 Min.
    Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

    Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

    Visit https://www.peervoice.com/NYE860 to view the entire programme with slides. After completing “Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy”, participants will be able to: Assess current treatment options for first-line management of advanced urothelial carcinoma (aUC), including maintenance therapy; Identify patients with aUC who may benefit from maintenance therapy; Formulate appropriate maintenance therapy plans for patients with aUC; and Identify emerging therapies, including maintenance therapies, for the management of aUC.

    • 16 Min.
    Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria

    Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria

    Visit https://www.peervoice.com/ZHK860 to view the entire programme with slides. After completing “Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria”, participants will be able to: Discuss the benefits and limitations of C5 inhibitors in the treatment of paroxysmal nocturnal haemoglobinuria (PNH); Differentiate between breakthrough haemolysis (BTH) and extravascular haemolysis (EVH) in patients who are receiving a terminal complement inhibitor; Evaluate clinically significant EVH in patients with PNH based on signs and symptoms; and Discuss key data on proximal complement inhibitors for the treatment of PNH and their role in clinical practice.

    • 19 Min.
    Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer

    Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer

    Visit https://www.peervoice.com/RAS860 to view the entire programme with slides. After completing “Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer”, participants will be able to: Identify non-invasive molecular testing approaches to identify biomarkers of interest in patients with metastatic colorectal cancer (mCRC); Formulate individualised first-line treatment plans for patients with mCRC, based on factors such as molecular status and primary tumour location; and Assess the clinical relevance of clinical trial data evaluating novel combination therapies for the management of mCRC.

    • 34 Min.
    Fatos Pinar Topsever, MD / Jennifer Green, MD - CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes

    Fatos Pinar Topsever, MD / Jennifer Green, MD - CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes

    Visit https://www.peervoice.com/QKR860 to view the entire programme with slides. After completing “Fatos Pinar Topsever, MD / Jennifer Green, MD - CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes”, participants will be able to: Use recommended screening tests to identify chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM); Evaluate current efficacy and safety evidence guiding the use of novel treatments for CKD in T2DM; and Apply best practices for the initiation and management of novel therapies for treatment of CKD and T2DM.

    • 33 Min.

Top‑Podcasts in Wissenschaft

Aha! Zehn Minuten Alltags-Wissen
WELT
Sternengeschichten
Florian Freistetter
KI verstehen
Deutschlandfunk
Das Wissen | SWR
SWR
radioWissen
Bayerischer Rundfunk
ZEIT WISSEN. Woher weißt Du das?
ZEIT ONLINE

Das gefällt dir vielleicht auch

Mehr von PeerVoice

PeerVoice Oncology & Haematology Audio
PeerVoice
PeerVoice Immunology & Infectious Disease Audio
PeerVoice
PeerVoice Endocrinology & Metabolic Disorders Video
PeerVoice
PeerVoice Digestive Diseases Audio
PeerVoice
PeerVoice Oncology & Haematology Video
PeerVoice
PeerVoice Internal Medicine Video
PeerVoice